This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management

Authoring team

This is a complex subject; however principles can be summarised as:

  • interruption of transmission. There is evidence that AZT given to an HIV positive mother from the 16th week of gestation until delivery, and then to six weeks old in the baby can reduce transmission by up to 60%. There is also evidence to suggest that elective caesarian section may be protective to the infant.
  • prevention of superinfection - here immunisation has an important role to play, with septrin given regularly to try to prevent pneumocystis
  • social and psychological care

Treatment options are the same as in adults - there is an increasing use of combination antiretroviral therapy (ART) and also prophylaxis against Pneumocystic carinii pneumonia (PCP). These management changes have been reflected in a major improvement in the prognosis of children with HIV infection, especially in the first year of life (1).

Treatment of HIV-infected pregnant women is described in the menu option below.

Reference:

  1. The European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children; the first 10 years of life.Pediatrics 2001;108:116-22

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.